CAI
Caris Life Sciences·NASDAQ
--
--(--)
--
--(--)
4.74 / 10
Netural
Fund flow analysis scores 7.82/10, highlighting robust capital movement with positive trends in block, medium, and extra-large flows, despite some small and large inflow challenges. Analyst sentiment is neutral, with two Neutral ratings and no historical win-rate advantage. Overall, the stock benefits from positive funding but lacks strong analyst endorsement.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-22
InstitutionCanaccord Genuity
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for CAI?
- CAI holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.74/10 (Netural).
